Highlight Pharmaceutical TYK2/JAK1 Inhibitor Strong to Sea at US $0.95 billion-Thinking about Innovative Drugs to Sea

2023Year3Month22day,Biohaven Ltd (NYSE: BHVN)Announced the cooperation with Hangzhou GaOGuang Pharmaceutical Co., Ltd (“Highlight Pharmaceutical”) entered into an exclusive development and licensing agreement outside the Greater China region to introduce our research and development.TLL-041.According to the agreement,Biohavenwill pay2000Payment by million heads of state (cash+stocks),9.5Milestones and multi-level, proportional sales shares.BiohavenWill be in2023 The clinical phase I was launched in, and the two sides collaborated globally for clinical development.TLL-041It is the world's first highly selective dual target with the ability to cross the blood-brain barrier.TYK2/JAK1inhibitors.TYK2andJAK1is to deal with a range of pro-inflammatory cytokinesSTATpathway regulators; inhibition of these kinases may play an important role in reducing inflammation in neurological diseases, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis.

The above cases of innovative drugs going to sea inevitably cause innovative pharmaceutical companies to thinkThe question of "how innovative drugs can go to sea in order to avoid detours"; in this regard, Yang Jianxin, CEO of Cornerstone Pharmaceuticals, Hu Yunfu, chief medical officer of Pan Shengzi, Wang Qingmei, senior vice president of Hutchison Pharmaceuticals, and head of external innovation and foreign cooperation in Novo Nordisk Asia PacificThe JennySheng Yanci, General Manager of Global Strategy and Project Management, Fuhong Hanlin, is hosted by Pan-born Children,EThe "Drug Precision" column hosted by the drug manager launched the first issue.“Help global development cooperation, domestic new drugs to the sea.”The following two consensuses were reached at the symposium:First, the road to internationalization must be taken, especiallyBiopharma; Second, the current appropriate way to go to sea is“Borrowing a boat to go to sea”rather than themselves."Ship to Sea".

The first thing to "borrow a boat to go to sea" is that its own products are excellent.In this regard, Yang Jianxin believes that there areFirst-in-classThe product is best; in addition, if the product hasBest-in-classThe potential, including efficacy, new indications and safety, such products have the potential to go to sea.Second, the attributes of the product affect the choice of time nodes for external cooperation.In this regard, Wang Qingmei believes that cooperation can be started at any time. The difference lies in the difference in the down payment, but the milestone payment for cooperation is almost the same. For havingFICPotential products, you can look for partners early; for products with no significant differences, you can wait until later in the clinic to make differences before seeking cooperation.”.Finally, a fit partner is seen as the second most important conditionIn this regard, Hu Yunfu believes that at present, it is going through a process of industry liquidation, and many non-compliant enterprises will be eliminated, so it is very important to choose stable and reliable partners. Using companion diagnostics as an example, the Panzoon American Laboratory passedCAP,CLIACertification, hoping to build industry benchmarks in the two important markets of China and the United States, and better serve global pharmaceutical companies at the same time.“China-US Double Newspaper”.Furthermore, in additionIn addition to "reliable", the choice of partners should follow "complementary".Capital is on the one hand, and more importantly, it brings international clinical benefits to Chinese pharmaceutical companies.Know how. In Wang Qingmei's view, signing the contract is only the beginning, and more is the follow-up project promotion of both parties. This process is extremely testing the teams of both parties.“Want to know whether to take a down payment or really make the product.

The above summary hopes to bring some new inspiration to innovative pharmaceutical companies that want to go to sea.